Aandeel ONWARD MEDICAL BRU:ONWD.BL, NL0015000HT4

quote:

biobert schreef op 20 december 2024 21:20:

Dear Investors and Friends,

We announced US FDA market authorization of our ARC-EX System just 24 hours ago, but already the global news coverage has been impressive. It is gratifying to see the issues of the spinal cord injury community garner so much attention.

Most notable is a?three-minute segment?which aired today on ABC News’ “Good Morning America”, calling ARC-EX a “game-changer for the 300,000 Americans with spinal cord injury.” ?
The correspondent covering this milestone for ABC News is Will Reeve, son of Christoper Reeve. His story centered around trial participant Jessie Owen, who spoke about the ways her life was impacted by our therapy. Jessie has regained the ability to perform routine tasks like opening a jar of peanut butter and feeding her kids…progress which is “enough to make meaning in my life.”

The story was aired nationally in the US and locally by dozens of local ABC affiliate television stations across the country. The television segment was accompanied by this?ABC News digital?online story.

As Will told the audience, “Progress in spinal cord injury research is usually measured in decades, so this is a long time coming. And to be able to say this is here and is getting out to people who need it is a big moment.”

We appreciate your support as we have worked to achieve this landmark. We are all looking forward to seeing the impact ARC-EX can make in the coming months, addressing the unmet needs of those with SCI.





Dave Marver
CEO

ARC-EX Indication for Use (US): The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation?in conjunction with functional task practice in the clinic?to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive).
Other Investigational Products: All other ONWARD Medical devices and therapies including ARC-IM and ARC-BCI are investigational and not available for commercial use.
Trademarks: ONWARD, ARC-EX, ARC-IM, ARC-BCI, and the stylized O-Logo are proprietary and registered trademarks of ONWARD Medical. Unauthorized use is strictly prohibited.

Door dit bericht van ceo Marver maandag verdere koersstijging?

quote:

biglion schreef op 20 december 2024 17:36:

[...]

>>>>>>>>

Yanmik,

Dat heb jij heel goed gezien en in welke aandelen heb jij jouw hebben en houden gestoken en hoeveel heeft het al echt opgebracht?

quote:

yanmik schreef op 21 december 2024 07:00:

[...]
Enkele voorbeelden:

Apple: ytd 32%
Amazon: ytd 48%
Broadcom: ytd 98%
Paypal: ytd 42%
Tesla: ytd 70%
IWDA etf: ytd 28%

uranium / quantum

quote:

psps schreef op 21 december 2024 11:03:

Sta ik gistermorgen voor de keuze Onward bijkopen of TKH i.v.m. belang HAL.
Wat een waardeloze stijging van de koers Onward. Spijt dat ik TKH niet gekocht heb!

quote:

psps schreef op 21 december 2024 11:03:

Sta ik gistermorgen voor de keuze Onward bijkopen of TKH i.v.m. belang HAL.
Wat een waardeloze stijging van de koers Onward. Spijt dat ik TKH niet gekocht heb!

quote:

Börs schreef op 21 december 2024 20:18:

[...]

Geduld … de onderliggende waarde van Onward zal vanzelf in de hoogte van de koers tot uitdrukking gaan komen.

quote:

yanmik schreef op 21 december 2024 07:00:

[...]
Enkele voorbeelden:

Apple: ytd 32%
Amazon: ytd 48%
Broadcom: ytd 98%
Paypal: ytd 42%
Tesla: ytd 70%
IWDA etf: ytd 28%

uranium / quantum